- ►annals.org AM Di Bisceglie, HS Conjeevaram, MW … - Annals of internal …, 1995 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg Add to Facebook
Add to Reddit Add to Technorati Add to Twitter What's this? ... Objective: To evaluate
ribavirin, an oral antiviral agent, as therapy for chronic hepatitis C. Cited by 268 - Related articles - BL Direct - All 4 versions
G Dusheiko, J Main, H Thomas, O Reichard, C Lee, A … - Journal of hepatology, 1996 - Elsevier Results: Ribavirin was significantly more effective than placebo in reducing and normalising
serum ALT levels: (55%) of ribavirin-treated patients vs (5%) placebo recipients had either normalisation
of the ALT levels or a reduction from baseline of at least 50% (p<0.001). ALT levels were ... Cited by 234 - Related articles - BL Direct - All 5 versions
HC Bodenheimer Jr, KL Lindsay, GL Davis, JH … - Hepatology, 1997 - interscience.wiley.com Hepatitis C is a common cause of chronic liver disease that may progress to cirrhosis. We conducted
a multicenter double-blind placebo-controlled trial of ribavirin 600 mg given orally twice daily
for 36 weeks with follow-up off therapy for an additional 16 weeks. Fifty-nine patients with ... Cited by 290 - Related articles - BL Direct - All 3 versions
O Reichard, J Andersson, R Schvarcz, O Weiland - The Lancet, 1991 - Elsevier We evaluated oral ribavirin as therapy for chronic hepatitis C infection in a pilot study including
10 patients. Patients (7 men, 3 women; mean age 40 years, range 23-54) all had biopsy-proven
chronic non-A, non-B hepatitis and were repeatedly positive for antibodies to hepatitis C ... Cited by 178 - Related articles - All 5 versions
AM Di Bisceglie, M Shindo, TL Fong, MW Fried, MG … - Hepatology, 1992 - interscience.wiley.com Interferon- therapy is of proven efficacy in chronic hepatitis C, but it is not universally effective
and may be associated with intolerable side effects. Ribavirin is a nucleoside analog with a broad
spectrum of antiviral action. We conducted an uncontrolled pilot study of ribavirin therapy ... Cited by 221 - Related articles - BL Direct - All 3 versions
S Brillanti, J Garson, M Foli, K Whitby, R Deaville, C … - Gastroenterology, 1994 - ncbi.nlm.nih.gov BACKGROUND/AIMS: In chronic hepatitis C, interferon alfa (IFN-alpha) therapy fails to achieve
a sustained response in approximately 75% of patients. Similarly, ribavirin induces only a transient
response. The aim of this study was to evaluate whether ribavirin and IFN-alpha in ... Cited by 218 - Related articles - BL Direct - All 4 versions
SW Schalm, BE Hansen, L Chemello, A Bellobuono, JT … - Journal of hepatology, 1997 - Elsevier Methods: A meta-analysis was carried out of individual patient data comprising about 90% of
the published experience with combination therapy. The study was set in four European
university-affiliated liver referral centers. A total of 186 individuals with chronic hepatitis C ... Cited by 184 - Related articles - BL Direct - All 6 versions
JH Hoofnagle, D Lau, H Conjeevaram, D … - Journal of Viral …, 1996 - interscience.wiley.com It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ... Cited by 47 - Related articles - BL Direct - All 2 versions
L Chemello, L Cavalletto, E Bernardinello, M … - Journal of …, 1995 - ncbi.nlm.nih.gov BACKGROUND: Chronic hepatitis C may lead to cirrhosis and hepatocellular carcinoma in a
subset of patients. Because response rates with interferon alfa therapy are unsatisfactory, new
therapies are needed. METHODS: We conducted a three-arm, randomized trial in 45 ... Cited by 133 - Related articles - BL Direct - All 2 versions
